Nektar Therapeutics (NKTR) Presents New Responder Data for Rezpegaldesleukin streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Seven abstracts to be presented demonstrating treatment effects of Bylvay® in two cholestatic liver diseases, progressive familial intrahepatic cholestasis and Alagille syndrome Data to be. | June 12, 2023
A 4 mg dose of baricitinib was associated with significant improvement over placebo in a number of efficacy parameters in patients with moderate to severe atopic dermatitis, according to a study. “Baricitinib, an oral selective Janus kinase (JAK)1/JAK2 inhibitor, is approved in many countries for moderate-to-severe atopic dermatitis (AD) in adult patients who are candidates
Phase 2 results show a reduction in itch in patients with notalgia paresthetica, but 19% of patients discontinued the trial because of side effects compared with 6% in the placebo group.
MILAN — Pediatric patients experienced improved psoriasis symptoms and quality of life with ixekizumab treatment, according to a poster presented at the European Academy of Dermatology and Venereology Congress.
“About 1% of children and adolescents worldwide are affected by plaque psoriasis (PsO),” Andreas Pinter, MD, medical director of clinical research and senior physician in